Aileron Therapeutics
Monday, February 26, 2024
Royale
Respiratory
Aileron is developing novel medicines to provide better treatment options for patients with life-threatening pulmonary conditions. With its acquisition of Lung Therapeutics, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases. Lung Therapeutics’ lead clinical programs include LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE).
State
Texas
Country
United States
Website
https://aileronrx.com/
CEO/Top Company Official
Manuel Aivado, MD, PhD
Lead Product in Development
LTI-03
Development Phase of Primary Product
Phase I
Number Of Unlicensed Products
2
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}